Kinoxis Therapeutics Pty Ltd., of Melbourne, Australia, received an NIH National Institute of Drug Abuse grant for $4.6 million to fund preclinical and clinical development of Kinoxis' lead compound, KNX-100, for treating opioid withdrawal. The funding is connected to achieving certain development milestones, as KNX-100 is in a phase I study in healthy volunteers.